Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000261100 | SCV000330814 | likely pathogenic | not provided | 2019-05-28 | criteria provided, single submitter | clinical testing | Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Not observed at a significant frequency in large population cohorts (Lek et al., 2016); Has not been previously published as pathogenic or benign to our knowledge |
Greenwood Genetic Center Diagnostic Laboratories, |
RCV001814140 | SCV002061690 | likely pathogenic | Actin accumulation myopathy; Congenital myopathy with fiber type disproportion; Progressive scapulohumeroperoneal distal myopathy | 2021-11-05 | criteria provided, single submitter | clinical testing | PVS1, PM2 |
Labcorp Genetics |
RCV002519066 | SCV003295770 | pathogenic | Actin accumulation myopathy | 2022-02-03 | criteria provided, single submitter | clinical testing | ClinVar contains an entry for this variant (Variation ID: 280863). This premature translational stop signal has been observed in individual(s) with autosomal recessive ACTA1-related conditions (PMID: 19562689). This variant is present in population databases (rs371410845, gnomAD 0.0009%). This sequence change creates a premature translational stop signal (p.Tyr145*) in the ACTA1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in ACTA1 are known to be pathogenic (PMID: 19562689). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. For these reasons, this variant has been classified as Pathogenic. |